Increase of mobilized CD34-positive peripheral blood progenitor cells in patients with Hodgkin's disease, non-Hodgkin's lymphoma, and cancer of the testis

Bone Marrow Transplantation

Volumn 17, Issue 5, 1996, Pages 709-713

  Zeller, W ^a,c   Gutensohn, K ^b   Stockschlader M ^a   Dierlamm, J ^a   Kroger N ^a   Koehne, G ^a   Hummel, K ^b   Kabisch, H ^c   Weh, H J ^a   Kuhnl P ^b   Hossfeld, D K ^a   Zander, A R ^a  

^a Bone Marrow Transplantation Unit   (Germany)

^b Dept Transfusion Medicine ^*

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

G CSF dose; Mobilization of PBPC

Indexed keywords

CD34 ANTIGEN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADOLESCENT; ADULT; ARTICLE; BLOOD CELL COUNT; CLINICAL TRIAL; COLONY FORMING UNIT GM; DRUG EFFICACY; FEMALE; HEMATOPOIESIS; HODGKIN DISEASE; HUMAN; HUMAN CELL; LEUKAPHERESIS; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TESTIS CANCER;

ADOLESCENT; ADULT; ANTIGENS, CD34; BLOOD CELL COUNT; COLONY-FORMING UNITS ASSAY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FILGRASTIM; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HODGKIN DISEASE; HUMANS; LEUKAPHERESIS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; TESTICULAR NEOPLASMS; TRANSPLANTATION, AUTOLOGOUS;

EID: 15844388368     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Korbling M, Juttner CA, Henon P, Kessinger A. Autologous blood stem cell versus bone marrow transplantation. Bone Marrow Transplant 1992; 10 (Suppl. 1): 144-148.
2. Sheridan WP, Begley CG. Juttner CA et al. Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 1992; 339: 640-644.
3. To LB, Roberts MM, Haylock DN et al. Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Transplant 1992; 9: 277-284.
4. To LB, Russell J, Moore S, Juttner CA. Residual leukemia cannot be detected in very early remission peripheral blood stem cell collections in acute non-lymphoblastic leukemia. Leukemia Res 1987; 11: 327-329.
5. Craig JL, Langlands K, Parker AC, Anthony RS. Molecular detection of tumor contamination in peripheral blood stem cell harvests. Exp Hematol 1994; 22: 898-902.
6. Korbling M, Holle R, Haas R et al. Autologous blood stemcell transplantation in patients with advanced Hodgkin's disease and prior radiation to the pelvic site. J Clin Oncol 1990; 8: 978-985.
7. DeLuca E, Sheridan WP, Watson D et al. Prior chemotherapy does not prevent effective mobilisation by G-CSF of peripheral blood progenitor cells. Br J Cancer 1992; 66: 893-899.
8. To LB, Haylock DN, Dyson PG et al. An unusual pattern of hemopoietic reconstitution in patients with acute myeloid leukemia transplanted with autologous recovery phase peripheral blood. Bone Marrow Transplant 1990; 6: 109-114.
9. Szer J, Juttner CA. To LB. Post-remission therapy for acute myeloid leukemia with blood-derived stem cell transplantation. Results of a collaborative phase II trial. Int J Cell Clon 1992; 10 (Suppl. 1): 114-116.
10. Reiffers J, Castaigne S. Tilly H et al. Hematopoietic reconstitution after autologous blood stem cell transplantation: a report of 46 cases. Plasma Ther Transfus Technol 1987; 8: 360-362.
11. Sheridan WP, Begley CG, To LB et al. Phase II study of autologous filgrastim (G-CSF)-mobilized peripheral blood progenitor cells to restore hemopoiesis after high-dose chemotherapy for lymphoid malignancies. Bone Marrow Transplant 1994: 14: 105-111.
12. Haas R, Hohaus S, Goldschmidt H et al. Hematopoietic growth factors for the mobilization of peripheral blood stem cells. J Hematother 1993; 2: 357-359.
13. Peters WP, Rosner G, Ross M et al. Comparative effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. Blood 1993; 81: 1709-1719.
14. Bensinger WI, Longin K, Appelbaum F et al. Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony-stimulating factor (rhG-CSF): an analysis of factors correlating with the tempo of engraftment after transplantation. Br J Haematol 1994; 87: 825-831.
15. Bensinger W, Singer J, Appelbaum F et al. Autologous transplantation with peripheral blood mononuclear cells collected after administration of recombinant granulocyte stimulating factor. Blood 1993; 81: 3158-3163.
16. Chao NJ, Schriber JR, Grimes K et al. Granulocyte colony-stimulating factor 'mobilized' peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy. Blood 1993; 81: 2031-2035.
17. Nademanee A, Sniecinski I, Schmidt GM et al. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells. J Clin Oncol 1994; 12: 2176-2186.
18. Bolwell BJ, Fishleder A, Andresen SW et al. G-CSF primed peripheral blood progenitor cells in autologous bone marrow transplantation: parameters affecting bone marrow engraftment. Bone Marrow Transplant 1993; 12: 609-614.
19. Teshima T, Harada M, Takamatsu Y et al. Granulocyte colony-stimulating factor (G-CSF)-induced mobilization of circulating haemopoietic stem cells. Br J Haematol 1993; 84: 570-573.
20. Hohaus S, Goldschmidt H, Ehrhardt R, Haas R. Successful autograftig following myeloablative conditioning therapy with blood stem cells mobilized by chemotherapy plus rhG-CSF. Exp Hematol 1993; 21: 508-514.
21. Dreger P. Marquardt P, Haferlach T et al. Effective mobilisation of peripheral blood progenitor cells with 'Dexa-BEAM' and G-CSF: timing of harvesting and composition of the leukapheresis product. Br J Cancer 1993; 68: 950-957.
22. 2 plus rhG-CSF for mobilization of circulating progenitor cells in malignant lymphomas. Int J Artif Org 1993; 16 (Suppl. 5): 30-34.
23. Neben S, Marcus K, Mauch P. Mobilization of hematopoietic stem and progenitor cell subpopulations from the marrow to the blood of mice following cyclophosphamide and/or granulocyte colony-stimulating factor. Blood 1993; 81: 1960-1967.
24. Teshima T, Harada M, Takamatsu Y et al. Cytotoxic drug and cytotoxic drug/G-CSF mobilization of peripheral blood stem cells and their use for autografting. Bone Marrow Transplant 1992; 10: 215-220.
25. Schwartzberg LS, Birch R. Hazelton B et al. Peripheral blood stem cell mobilization by chemotherapy with and without recombinant human granulocyte colony-stimulating factor. J Hematother 1992; 1: 317-327.
26. Craig JI, Anthony RS, Stewart A et al. Peripheral blood stem cell mobilization using high-dose cyclophosphamide and G-CSF in pretreated patients with lymphoma. Br J Haematol 1993; 85: 210-212.
27. Brugger W, Birken R, Bertz H et al. Peripheral blood progenitor cells mobilized by chemotherapy plus granulocyte colony-stimulating factor accelerate both neutrophil and platelet recovery after high-dose VP16, ifosfamide and cisplatin. Br J Haematol 1993; 84: 402-407.
28. Liu KY, Akashi K, Harada M et al. Kinetics of circulating haematopoietic progenitors during chemotherapy-induced mobilization with or without granulocyte colony-stimulating factor. Br J Haematol 1993; 84: 31-38.
29. Dührsen U, Villeval JL. Boyd J et al. Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood 1988; 72: 2074-2081.
30. Gabrilove JL. Biological effects and clinical applications of human colony-stimulating factors. Cancer Chemother Biol Response Modif 1988; 10: 492-506.
31. Socinski MA, Elias A. Schnipper L et al. Granulocyte-macrophage colony-stimulating factor expands the circulating haematopoietic progenitor cell compartment in man. Lancet 1988; i: 1194-1198.
32. Villeval JL, Duehrsen U, Morstyn G, Metcalf D. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on progenitor cells in patients with advanced malignancies. Br J Haematol 1990; 74: 36-44.
33. Siena S. Bregni M, Brando B et al. Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients. Blood 1991; 77: 400-409.
34. To LB, Dyson PG, Juttner CA. Cell-dose effect in circulating stem-cell autografting. Lancet 1986; ii: 404-405.
35. To LB, Juttner CA. Annotation. Peripheral blood stem cell autografting: a new therapeutic option for AML? Br J Haematol 1987; 66: 285-288.
36. + cells. Blood 1994; 84: 2930-2939.
37. + cells with a different antigenic profile compared with use during steady-state hematopoiesis. Bone Marrow Transplant 1994; 14: 827-832.
38. Fruehauf S, Haas R, Conradt C et al. Peripheral blood progenitor cell (PBPC) counts during steady-state hematopoiesis allow to estimate the yield of mobilized PBPC after filgrastim (R-metHuG-CSF)-supported cytotoxic chemotherapy. Blood 1995; 85: 2619-2626.
39. + cells and unseparated peripheral blood progenitor cells mediate identical hematopoietic engraftment after high-dose VP16, ifosfamide. carboplatin, and epirubicin. Blood 1994; 84: 1421-1426.
40. Haas R, Moehle R. Fruehauf S et al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994; 83: 3787-3794.